安科生物 (300009)

ANHUI ANKE BIOTECHNOLOGY (GROUP)CO.,LTD.

ASZ

Tags

AI HealthcareArtificial Intelligence (AI)ImmunotherapyInnovative DrugsPharmaceutical ManufacturingGuozheng Growth IndexGene ConceptSmall Cap GrowthPrivate HospitalsHepatitis ConceptMargin Trading and Securities LendingAssisted ReproductionChiNext 200 IndexChiNext 300 IndexChiNext InnovationChiNext Blue ChipChiNext Healthcare

K-Line Chart

No K-line data

Stock Details

1. Key Indicators

  • Total Shares(W): 167252.13
  • Circulating A-Shares(W): 122957.78
  • Earnings Per Share(RMB): 0.3300
  • Net Assets Per Share(RMB): 2.4926
  • Operating Revenue(W RMB): 196259.01
  • Total Profit(W RMB): 64868.42
  • Net Profit Attributable to Parent(W RMB): 55148.33
  • Net Profit Growth Rate(%): -6.48
  • Weighted Return on Equity(%): 13.5900
  • Operating Cash Flow Per Share(RMB): 0.3320
  • Undistributed Profit Per Share(RMB): 1.0490
  • Capital Reserve Per Share(RMB): 0.2735

2. Main Business

The main business covers:

  • Research, production, and sales of genetic engineering drugs
  • Research, production, and sales of biological detection reagents

3. Company Basic Information

  • Company Name: Anhui Anke Biotechnology (Group) Co., Ltd.
  • Listing Date: 2009-10-30
  • Industry: Pharmaceutical Manufacturing
  • Address: No. K-1, Haiguan Road, High-tech Zone, 669 Changjiang West Road, Hefei City, Anhui Province
  • Website: www.ankebio.com
  • Company Profile: The Company was established as a joint stock limited company through the overall restructuring of Anhui Anke Biotechnology High-tech Co., Ltd. by its original shareholders, with the audited net assets of RMB 24,043,800 as of August 31, 2000 converted into 24 million shares, approved by the Anhui Provincial Economic Restructuring Commission (Document No. Wan Ti Gai Han [2000] 77) and the Anhui Provincial People's Government (Approval Certificate No. Wan Fu Gu Zi [2000] 34). The Company obtained its Business License on September 28, 2000. Currently, the Company's total share capital is 63 million shares.

4. Top 10 Circulating Shareholders

Rank Institution Name Institution Type Shares Held (W) Percentage Held (%)
1 Hong Kong Securities Clearing Company Ltd. Northbound Capital 1952.26 1.60
2 China Merchants Guozheng Bio-medicine Index Securities Investment Fund (LOF) Class A Fund 1596.17 1.31
3 Yinhua CSI Innovative Pharmaceutical Industry Exchange Traded Fund Fund 1121.77 0.92
4 Southern CSI 1000 Exchange Traded Fund Fund 1070.74 0.88
5 Fullgoal Enhanced Return Bond Securities Investment Fund Class A Fund 900.00 0.74
6 China Securities Industry Rotation Hybrid Securities Investment Fund Class A Fund 564.68 0.46
7 China Securities Value Selection Hybrid Securities Investment Fund Class A Fund 370.05 0.30
8 China Securities Strategy Selection Hybrid Securities Investment Fund Class A Fund 254.96 0.21
9 Caitong Asset Management Health Industry Hybrid Securities Investment Fund Class A Fund 210.00 0.17
10 China Securities Quality Preferred One-Year Holding Hybrid Securities Investment Fund Class A Fund 78.54 0.06

5. Concept Sectors

  • Private Hospitals
  • Gene Concept
  • Immunotherapy
  • Artificial Intelligence
  • Assisted Reproduction
  • Hepatitis Concept
  • Innovative Drugs
  • AI Healthcare
  • Margin Trading & Securities Lending
  • Small Cap Growth
  • SZSE Growth Index
  • ChiNext 300
  • ChiNext Innovation
  • ChiNext Blue Chip
  • ChiNext Quality
  • ChiNext Pharmaceuticals
  • ChiNext 200

Remarks

  • Data update date: 2026-01-01
  • Data source: Public Market Information